NYSE · TFX
Healthcare · Medical - Instruments & Supplies
$124.52
Down-$1.07 (-0.85%)
Updated Sep 20, 2026, 10:57 AM
SID Score
4.4/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
TFX closed at $124.52 after 19 trading sessions, down 9.97% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $125.03 | $125.83 | $124.01 | $124.52 | 1.8M |
| Sep 17, 2026 | $126.95 | $128.88 | $125.05 | $125.59 | 867.13K |
| Sep 16, 2026 | $129.13 | $130.15 | $127.72 | $128.00 | 830.22K |
| Sep 15, 2026 | $130.40 | $130.40 | $126.18 | $129.02 | 803.75K |
| Sep 14, 2026 | $132.68 | $134.27 | $129.51 | $130.30 | 976.92K |
| Sep 11, 2026 | $133.23 | $134.09 | $128.98 | $130.99 | 572.75K |
| Sep 10, 2026 | $134.96 | $135.0825 | $130.985 | $132.00 | 763.24K |
| Sep 9, 2026 | $139.54 | $139.54 | $135.315 | $135.72 | 487.04K |
| Sep 8, 2026 | $136.66 | $139.105 | $134.775 | $137.00 | 496.12K |
| Sep 4, 2026 | $138.70 | $140.59 | $137.35 | $138.36 | 464.47K |
| Sep 3, 2026 | $140.01 | $143.23 | $138.64 | $139.96 | 704.9K |
| Sep 2, 2026 | $140.56 | $144.16 | $138.10 | $140.97 | 728.07K |
| Sep 1, 2026 | $140.19 | $143.05 | $135.20 | $140.48 | 565.01K |
| Aug 31, 2026 | $137.95 | $142.42 | $137.88 | $142.05 | 653.15K |
| Aug 28, 2026 | $137.35 | $140.57 | $137.35 | $139.67 | 429.36K |
| Aug 27, 2026 | $136.55 | $138.51 | $136.55 | $137.71 | 370.58K |
| Aug 26, 2026 | $139.14 | $140.17 | $137.955 | $138.74 | 533.77K |
| Aug 25, 2026 | $138.01 | $140.57 | $136.32 | $140.18 | 382.41K |
| Aug 24, 2026 | $138.87 | $140.275 | $137.71 | $138.31 | 645.09K |
The latest Smart Investors Daily articles mentioning TFX.
TFX research
Company profile and research snapshot.
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | Needham | Buy | — |
| Aug 11, 2026 | UBS | Neutral | — |
| Aug 10, 2026 | Truist Securities | Hold | — |
| Aug 7, 2026 | Piper Sandler | Overweight | — |
| Jul 31, 2026 | Needham | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 9, 2026
Looking back on surgical equipment & consumables - specialty stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Teleflex (NYSE:TFX) and its peers.
Yahoo · Sep 8, 2026
WAYNE, Pa., September 08, 2026--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective September 8, 2026.
Yahoo · Sep 4, 2026
Thermo Fisher's growth is gaining momentum as acquisitions strengthen its life sciences reach, but macro risks and competition remain concerns.
Yahoo · Sep 4, 2026
WAYNE, Pa., September 04, 2026--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it will showcase innovative technologies at CIRSE 2026 in Copenhagen, reinforcing its commitment to advancing innovation for healthcare providers. Among the featured technologies will be the Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System. This technology is supported by the previously presented BIONETIC-TRA study, an investigator-initiated study with
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TFX.
